Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5130102 | 0.97 | KIF11 (0.33) | KIF11KMT2APSEN1PSEN2APH1B | |
| SCHEMBL5131094 | 0.83 | MAOB (0.39) | KIF11PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5132869 | 0.83 | MAOB (0.39) | KIF11PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6870819 | 0.79 | HDAC1 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5133980 | 0.78 | PSEN1 (0.36) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5133388 | 0.78 | HRH3 (0.45) | — | |
| SCHEMBL5133406 | 0.77 | PSEN1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5133263 | 0.77 | SIGMAR1 (0.45) | — | |
| SCHEMBL5132911 | 0.76 | LSS (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5133365 | 0.76 | LSS (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449483-B2 | Heteroaromate OSC inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070099985-A1 | Heteroaromate OSC inhibitors | AEBI JOHANNES | 2007-05-03 | — | — | US | disclosed |
| US-7173043-B2 | Enzyme inhibitors for cyclases as anticholesterol agents or cardiovascular disorders | HOFFMANN-LA ROCHE INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050267200-A1 | Enzyme inhibitors for cyclases as anticholesterol agents or cardiovascular disorders | AEBI JOHANNES | 2005-12-01 | — | — | US | disclosed |
| US-6951879-B2 | Substituted benzo(b)thiophenes or benzoisothiazoles which inhibit 2,3-oxidosqualene-lanosterol cyclase which is required for the biosynthesis of cholesterol, ergosterol and other sterols | HOFFMANN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1334094-B1 | CHOLESTEROL LOWERING BENZO[B]THIOPHENES AND BENZO[D]ISOTHIAZOLES | HOFFMANN LA ROCHE (CH) | 2004-12-29 | — | — | EP | disclosed |
| US-20020086891-A1 | Heteroaromate OSC inhibitors | HOFFMAN-LA ROCHE INC. | 2002-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267200-A1 | Enzyme inhibitors for cyclases as anticholesterol agents or cardiovascular disorders | LSS, CYP51A1, CYP46A1 | KIF11 4807/4885KMT2A 3719/4885PSEN1 4135/4885 |
| US-20070099985-A1 | Heteroaromate OSC inhibitors | LSS, CYP51A1, CYP46A1 | KIF11 4751/4885KMT2A 3752/4885PSEN1 3834/4885 |
| US-20020086891-A1 | Heteroaromate OSC inhibitors | LSS, CYP51A1, CYP46A1 | KIF11 4751/4885KMT2A 3752/4885PSEN1 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.